TARS
Tarsus Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$90.78
+9.10%Year over year
Reported trailing growth
- Revenue
- +105.2%
- EBITDA
- +56.6%
- EBIT
- +50.5%
- EPS
- +53.2%
- Free cash flow
- +170.1%
- Operating cash flow
- +198.6%
Forward estimates
Based on analyst estimates
- Revenue
- +31.8%
- EBITDA
- -87.6%
- EPS
- -81.1%
Three-year CAGR
- Revenue
- +159.5%
- EBITDA
- +49.7%
- EBIT
- +41.1%
- Net income
- +42.5%
- EPS
- +48.2%
- Free cash flow
- +73.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026